Scripta Therapeutics

Founded in 2025 in Oxford, UK, Scripta Therapeutics is focused on developing solutions for neurodegenerative diseases.Scripta Therapeutics specializes in innovative drug discovery solutions, focusing on the manipulation of transcription factors to address neurodegenerative disorders such as Alzheimer’s, Parkinson’s, and ALS. The company employs advanced AI/ML models to identify and predict molecules and targets that modulate transcription factor activity, enabling the development of therapeutics aimed at halting or even reversing disease progression. Their approach starts with genome-wide mapping of transcription factors that drive disease, followed by validation of therapeutic candidates in pre-mapped, patient-derived models. Revenue is generated primarily through partnerships and collaborations with pharmaceutical companies seeking innovative approaches to drug discovery, particularly those that involve transcription factor modulation. The company’s flagship offerings include its transcription-factor-centered drug discovery services, which are integral to the therapeutic development process for its partners. The company intends to expand its reach into additional markets in North America and Europe by 2026, with a focus on releasing new therapeutic products that leverage their proprietary insights and AI-driven models.

1. Seed

   Nov 13, 2025

   Amount

   $12M

   Investors

   Locked